Skip to main content
Signal8
Launch Terminal

Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

NASDAQ:ALZNHealthcare
-0.82%$1.21
AH$1.21+0.00%vs close
Mkt Cap$5.84M
Float4.7M
O/S4.83M
Vol
$ Vol
RVOL
Inst Own52.0%
SI0.7%
Earnings
Dilution
Alzamend Neuro, Inc. logoNASDAQ:ALZN$1.21-0.82%
FormDescription
RW
SEC Filing
3
8-K
7.01,9.01
2
10-Q
Quarterly Report
7
4
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
PRE 14A
Preliminary Proxy Statement
6
S-1
Registration Statement
9
4/A
PRIMARY DOCUMENT
3/A
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
3
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
5
PRIMARY DOCUMENT
8-K
1.01,3.01,3.02,5.03,9.01
5
10-K
Annual Report
5
8-K
8.01,9.01
1
8-K
5.07,9.01
4
PRIMARY DOCUMENT

1-25 of 397

…